1-4 of 4
B Mahe
Close
Sort by
Journal Articles

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

S. Park, C. Kelaidi, S. Grabar, O. Beyne-Rauzy, S. Cheze, V. Bardet, M. Escoffre-Barbe, C. Ravoet, A. Ferrant, N. Vey, H. Dombret, B. Mahe, L. Mannone, L. Legros, L. Aljassem, A. Stamatoullas, D. Vassilief, M.C. Quarre, L. Ades, V. Andrieux, S. Giraudier, S. de Botton, N. Casadevall, P. Fenaux, F. Dreyfus
Journal: Blood
Blood (2006) 108 (11): 522.
https://doi.org/10.1182/blood.V108.11.522.522
Published: 2006
Journal Articles

RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM.

Christian Rose, MD, A. Stamatoulas, MD, D. Vassilief, MD, S. Brechignac, MD, O. Beyne-Rauzy, MD, F. Courtois, MD, M. Wemeau, MD, Agnes Guerci, MD, M.P. Chaury, MD, B. Lefs, MD, B. Mahe, MD, L. Roy, MD, Bruno Quesnel, PD, MD, F. Dreyfus, PD, MD, Pierre Fenaux, PD, MD
Journal: Blood
Blood (2006) 108 (11): 2661.
https://doi.org/10.1182/blood.V108.11.2661.2661
Published: 2006
Journal Articles

Thalidomide for the Treatment of Low Risk Myelodysplasia.

D. Bouscary, MD-PhD, M. C. Quarre, MD, D. Vassilief, MD, O. Beyne Rouzy, MD, A. Aouba, MD, C. Berthou, MD, C. Gardembas, MD, L. Sanhes, MD, A. Guerci, MD, B. Mahe, MD, A. Stamatoullas, MD, F. Bauduer, MD, J. J. Sotto, MD, L. Legros, MD-PhD, S. Vaultier, ARC, P. Fenaux, MD-PhD, F. Dreyfus, MD
Journal: Blood
Blood (2004) 104 (11): 1438.
https://doi.org/10.1182/blood.V104.11.1438.1438
Published: 2004
Journal Articles

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group

E Wattel, A Guerci, B Hecquet, T Economopoulos, A Copplestone, B Mahe, ME Couteaux, L Resegotti, V Voglova, C Foussard, B Pegourie, JL Michaux, E Deconinck, AM Stoppa, G Mufti, D Oscier, P Fenaux
Journal: Blood
Blood (1996) 88 (7): 2480–2487.
https://doi.org/10.1182/blood.V88.7.2480.bloodjournal8872480
Published: 1996